Comparative Pharmacology
Head-to-head clinical analysis: CIS PYRO versus INDIUM IN 111 CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS PYRO versus INDIUM IN 111 CHLORIDE.
CIS-PYRO vs INDIUM IN 111 CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cis-pyro is not a recognized pharmaceutical agent. No mechanisms data available.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Not applicable: CIS-PYRO is a pyrophosphate-based radiopharmaceutical used in cardiac imaging, not a therapeutic drug. Standard adult dose: 555-1110 MBq (15-30 mCi) intravenously once.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (IV); prolonged in renal impairment (up to 30 hours in ESRD).
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Primarily renal excretion: 65-80% unchanged in urine; biliary/fecal excretion accounts for 15-25%.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical